MCM
NGNE icon

MAI Capital Management’s Neurogene NGNE Stock Holding History

MAI Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$222 Buy
+11
New +$213 ﹤0.01% 4600

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

MAI Capital Management's NGNE Position: Q1 2026 in Review

MAI Capital Management opened a new position in Neurogene (NGNE) in Q1 2026: 11 shares worth $222. The stake represents ﹤0.01% of the portfolio and ranks #4600 among its holdings.

96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • MAI Capital Management held 11 shares of Neurogene worth $222 as of Q1 2026.
  • Neurogene was a new MAI Capital Management position in Q1 2026.
  • Neurogene made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4600 holding.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.